U.S. Micro-Solutions is partnering with Quess 360 to offer targeted HD Wipe Sampling for USP <800> compliance - Safer surfaces, Smarter monitoring!
USP <800> states the following: Environmental wipe sampling for HD surface residue should be performed routinely (e.g., initially as a benchmark and at least every 6 months, or more often as needed, to verify containment).
SOME RECOMMENDED AREAS to be sampled:
- Front grille within the C-PEC
- Cart beside the C-PEC
- Passthrough
- Floor in front of the C-PEC
- Armrest of a patient treatment chair
Hazardous Drugs Tested
| Groups of drugs | Limit of detection (ng/cm2) |
|---|---|
| Group 1F | |
| fluorouracil | 0.0089 |
| Group 1M | |
| methotrexate | 0.0044 |
| Group 2 | |
| cytarabine | 0.0111 |
| dacarbazine | 0.0022 |
| DOXOrubicin | 0.0444 |
| epirubicin | 0.0444 |
| gemcitabine | 0.0022 |
| melphalan | 0.0044 |
| Group 3 | |
| cyclophosphamide | 0.0022 |
| DOCEtaxel | 0.1333 |
| etoposide | 0.0089 |
| ifosfamide | 0.0022 |
| irinotecan | 0.0089 |
| methotrexate | 0.0044 |
| PACLitaxel | 0.0444 |
| PEMEtrexed | 0.0089 |
| topotecan | 0.0044 |
| vinBLAStine | 0.0444 |
| vinCRIstine | 0.0444 |
| Group 4 | |
| Platins (CISplatin, oxaliplatin, CARBOplatin) | 0.0022 |
| Group 5 | |
| All hazardous drugs in groups 1 to 4 | |
- Contribute to the assessment of safe practices in the workplace
- Evaluate potential HD exposure to staff (pharmacy, nursing, other personnel)
- Validate the effectiveness of decontamination procedures
- Assess the level of compliance of current procedures